NUTRIBAND Advances AVERSA™ Fentanyl Development Partnership

Introduction

NUTRIBAND INC (NASDAQ: NTRB), known in Korea as 뉴트리밴드, develops transdermal pharmaceutical products with a focus on abuse-deterrent drug delivery systems. The company’s lead technology, AVERSA™, incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of opioid-based medications. NUTRIBAND is headquartered in Orlando, Florida, and trades on the NASDAQ under the symbol NTRB.

Corporate Structure and Governance

Since acquiring 4P Therapeutics on August 1, 2018, NUTRIBAND shifted from consumer transdermal products to pharmaceutical transdermal systems. On December 1, 2020, the company added Pocono Pharmaceutical, a contract-manufacturing subsidiary, and it also maintains Active Intelligence, which develops sports recovery products. The Board of Directors oversees corporate governance, risk management, and financial performance, while an executive team, led by CEO Gareth Sheridan, manages day-to-day operations. NUTRIBAND holds global patent protection for AVERSA™ in 46 countries, including grants in the European Union, Australia, Japan, Mexico, Russia, China, Hong Kong, and Macao, with ongoing prosecution in the United States and Canada.

Transdermal patch by Pawel Czerwinski

Recent Developments and News

On February 20, 2025, NUTRIBAND formalized an exclusive product development partnership with Kindeva Drug Delivery. Under the agreement, Kindeva’s FDA-approved fentanyl patch system will be combined with AVERSA™ technology to develop AVERSA™ Fentanyl.
On April 30, 2025, CEO Gareth Sheridan published a letter to shareholders discussing progress toward commercialization, scale-up of manufacturing processes, and an $8.4 million non-brokered private placement completed in April 2024. Sheridan outlined plans for an Investigational New Drug (IND) application and a pivotal Human Abuse Liability clinical trial to support a New Drug Application (NDA).
On June 23, 2025, the company filed a post-effective amendment (Form POS AM) to update its registration statement, which may include revised disclosures on risk factors, use of proceeds, and strategic initiatives.
On LinkedIn, NUTRIBAND announced the completion of commercial scale-up for AVERSA™ Fentanyl manufacturing in partnership with Kindeva, moving toward potential FDA submission.

Financial and Strategic Analysis

As of July 2, 2025, at 11:14 AM EDT, NUTRIBAND shares traded at $10.44, reflecting a price increase of 30.17% on NASDAQ, with a volume of 1,065,267. Key metrics include a market capitalization of $116.45 million, 11.15 million shares outstanding, and a year-to-date share price increase of 119.75%.
According to trailing-twelve-month data:

• Revenue totaled $2.398 million, yielding a gross margin of 34.63%.
• The company reported a net loss that resulted in an EPS of –$0.90 and a net margin of –415.83%.
• EBITDA was $5.94 million, and the debt-to-equity ratio stood at 3.55%.
• The company’s beta is 1.31, and its forward P/E (NTM) is 23.73.

Strategically, NUTRIBAND aims to leverage a limited-development regulatory pathway by combining AVERSA™ with existing FDA-approved patches, potentially reducing clinical trial requirements. Public financing and the partnership with Kindeva are intended to support commercialization of AVERSA™ Fentanyl, with peak annual sales projections between $80 million and $200 million, alongside a subsequent AVERSA™ Buprenorphine candidate estimated at $70 million to $130 million in peak sales.

Market Position and Industry Context

Operating in the Health Care sector under Industrial Specialties, NUTRIBAND addresses the global opioid epidemic by enhancing the safety profile of transdermal opioids. Transdermal delivery has the potential to improve patient compliance and therapeutic outcomes compared to injections or oral formulations. The abuse-deterrent patch market is highly regulated and competitive, with few approved technologies for opioids. NUTRIBAND’s intellectual property portfolio and exclusive manufacturing partnership position it to be among the first to deliver an abuse-deterrent transdermal opioid system globally.

tl;dr

On June 23, 2025, NUTRIBAND filed a post-effective amendment updating its registration statement. In February 2025, it formalized an exclusive development partnership with Kindeva Drug Delivery to commercialize AVERSA™ Fentanyl, and in June 2025, it completed commercial scale-up of its manufacturing process. The company plans to submit an IND and initiate a pivotal Human Abuse Liability trial to support an NDA filing. Patent protection now covers 46 countries, and the next milestones include clinical supply manufacture and potential licensing opportunities ahead of FDA submission.